The veterinary diagnostics products market is projected to reach US$16.68 billion by 2031 from US$8.68 billion in 2024. The market is estimated to register a CAGR of 9.9% during 2025-2031. Major factors driving the market growth include a surging prevalence of zoonotic diseases, soaring initiatives for animal health, growing pet ownership, and companion animal adoption are propelling the adoption of veterinary diagnostics products. Further, developing cost-effective diagnostic solutions for rural markets will likely boost the market during the forecast period. However, shortage of skilled veterinary professionals, high cost of veterinary diagnostic kits and associated equipment, and inadequate infrastructure and accessibility in rural areas are among the market deterrents.

Organizations, including the WHO and the WOAH have launched global awareness campaigns emphasizing the role of vaccination in controlling zoonotic diseases. The WHO's Global Strategic Plan to End Human Deaths from Dog-Mediated Rabies by 2030 boosts initiatives to promote vaccine adoption on a large scale. The increasing availability of information on animal health through digital platforms, veterinary organizations, and public campaigns is boosting the adoption of veterinary healthcare products, including pharmaceuticals and medical devices. The rise of social media and online resources has empowered pet owners and farmers to learn about the risks of preventable diseases, including zoonotic ones such as rabies and leptospirosis, which can be transmitted from animals to humans.

The inter-ministerial scientific initiative led by the Indian Council of Medical Research (ICMR) in 2025 focuses on real-time zoonotic spillover surveillance at high-risk human-wildlife interfaces using advanced molecular diagnostic arrays. Public-private partnerships involving companies such as Tetracore and diagnostic startups facilitate kit development specifically for endemic diseases in regions such as Andhra Pradesh and Odisha.

The Indian Council of Agricultural Research (ICAR)-National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI) developed diagnostic kits such as the Bluetongue Sandwich ELISA as part of the 'Make in India' initiative in October 2019. These were deployed across 600 districts in 2024, per ICAR's 2023-24 annual report. The National Animal Disease Reporting System (NADRS 2.0), covering 652 districts, enables real-time disease monitoring, facilitating rapid kit deployment during outbreaks in 2023. In June 2024, the Department of Animal Husbandry and Dairying (DAHD) and the Ministry of Fisheries, Animal Husbandry, and Dairying signed an agreement to upgrade the Biocontainment Facility at CCS National Institute of Animal Health (CCSNAIH). This agreement strengthens the diagnostic testing capabilities of FMD, Brucella, PPR, and CSF vaccines under the LH&DC program. With governments, veterinarians, and global organizations working together to highlight the importance of preventive care, the adoption of pharmaceuticals and medical devices for companion animals and livestock has seen a significant rise. Thus, growing campaigns and initiatives drive the growth of the veterinary diagnostic products market.

The comparative company analysis evaluates and categorizes the veterinary diagnostics products market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Veterinary Diagnostics Products market. The key market players are Zoetis Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd, Bionote Inc., Gold Standard Diagnostics Budapest Kft., Ubio Biotechnology Systems Pvt Ltd, Secure Diagnostics Pvt Ltd, InBios International Inc., VMRD Inc., and Fujifilm Corp.

In terms of animal type, the veterinary diagnostics products market is bifurcated into companion animals and livestock animals. The companion animal segment held a larger market share in 2024, owing to the higher adoption of pets worldwide.

Based on product, the veterinary diagnostics products market is categorized into kits, reagents, and analyzers. The kits and reagents segment accounted for the largest share of the veterinary diagnostics products market in 2024. Several government programs and initiatives to develop innovations foster a favorable environment for veterinary diagnostics, leading to market growth in the coming years and increasing adoption of advanced kits and reagents for better animal health outcomes. The global market is experiencing growth in the launch and availability of veterinary diagnostic kits and reagents, driven by international initiatives such as the One Health approach and increased focus on animal health. Collaborative efforts by organizations like the World Organisation for Animal Health (WOAH), the Food and Agriculture Organization (FAO), and the World Health Organization (WHO) have spurred the development of innovative diagnostic tools by global institutions and companies. In June 2025, bioM?rieux launched the VETFIRE PCR kit for detecting equine infectious respiratory diseases, enhancing rapid diagnostics in veterinary settings. Additionally, in early 2025, Zoetis introduced the Vetscan OptiCell, an AI-powered point-of-care hematology analyzer designed for quick blood analysis in companion animals and livestock, announced at VMX 2025. In August 2025, the Government of India launched five innovative veterinary diagnostic tools at during the inauguration of India's State-of-the-Art Animal Stem Cell Biobank and Animal Stem Cell Laboratory at the National Institute of Animal Biotechnology (NIAB), Hyderabad.

By application, the veterinary diagnostics products market is bifurcated into infectious diseases and non-infectious diseases. The infectious diseases segment held a larger market share in 2024, owing to the high prevalence of infectious diseases.

Based on end users, the veterinary diagnostics products market is categorized into public healthcare facilities and private healthcare facilities. The public healthcare facilities segment held a larger share of the market in 2024. Public healthcare facilities play a crucial role as primary users of veterinary diagnostic products. These facilities often monitor and control zoonotic diseases transmitted between animals and humans.

Companies operating in the veterinary diagnostics products market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key veterinary diagnostics products market players are listed below.

In September 2025, FUJIFILM Healthcare Europe announced the European launch of the FUJI DRI-CHEM AU20V, an enhanced in-house diagnostics measurement device for veterinary use. Designed to provide rapid laboratory-quality results, this is the latest edition to FUJIFILM's FVET veterinary diagnostics portfolio.

In July 2025, Ceva Animal Health (Ceva) inaugurated its new global headquarters in Libourne, France. The new headquarters hosts 450 employees across 11,000 m? and four floors, bringing together the group's main strategic functions all working towards a shared ambition.

In May 2025, Zoetis Inc. announced its newest and largest diagnostics reference laboratory at the UPS Healthcare Labport facility at Louisville Muhammad Ali International Airport. This strategic expansion represents a significant milestone in Zoetis' ongoing investment in diagnostics innovation, which aims to advance animal care through faster, more precise, and more accessible testing services for veterinarians and pet owners across the US.

In September 2024, Zoetis Inc. unveiled its new hematology analyzer Vetscan OptiCell, a cartridge-based, AI-powered diagnostic tool that provides advanced Complete Blood Count (CBC) analysis. The analyzer represents a significant leap in technology and offers meaningful time, cost and space savings for veterinary care teams, to enable better patient outcomes and allows for a more efficient clinic workflow.

In December 2023, Bionote USA released a new canine and feline Symmetric Dimethylarginine (SDMA) test in its Vcheck F line. This test provides quantitative levels of this biomarker to veterinarians at the point of care. Unlike some SDMA offerings, which are only included on a larger panel with other tests, the Vcheck SDMA test is an independent biomarker test.